nach oben

07.03.2024 | original article

Significance of plasma relaxin-2 levels in patients with primary hypertension and type 2 diabetes mellitus

verfasst von: Olena Pankova, Oleksii Korzh

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten

Summary

Background

This study aimed to evaluate plasma relaxin‑2 (RLN-2) levels in patients with arterial hypertension (AH) and their relationships with clinical and laboratory parameters.

Methods

The study involved 106 hypertensive patients, including 55 with type 2 diabetes mellitus (T2DM), and 30 control subjects. Plasma RLN-2 levels were measured using an enzyme-linked immunosorbent assay kit.

Results

RLN-2 levels were reduced in patients with AH compared to healthy volunteers (p < 0.001), and hypertensive patients with T2DM had lower RLN-2 levels than those without impaired glucose metabolism (p < 0.001). RLN‑2 was negatively correlated with systolic blood pressure (SBP) (p < 0.001) and anthropometric parameters such as body mass index (BMI; p = 0.027), neck (p = 0.045) and waist (p = 0.003) circumferences, and waist-to-hip ratio (p = 0.011). RLN‑2 also had inverse associations with uric acid levels (p = 0.019) and lipid profile parameters, particularly triglycerides (p < 0.001) and non-HDL-C/HDL‑C (p < 0.001), and a positive relationship with HDL‑C (p < 0.001). RLN‑2 was negatively associated with glucose (p < 0.001), insulin (p = 0.043), HbA1c (p < 0.001), and HOMA-IR index (p < 0.001). Univariate binary logistic regression identified RLN‑2 as a significant predictor of impaired glucose metabolism (p < 0.001).

Conclusions

Decreased RLN-2 levels in patients with AH and T2DM and established relationships of RLN‑2 with SBP and parameters of glucose metabolism and lipid profile suggest a diagnostic role of RLN‑2 as a biomarker for AH with T2DM.

World Health Organization (2020) Global Health Estimates 2019 Summary Tables: Deaths by Cause, Age And Sex, by World Bank Income Group, 2000–2019. https://www.who.int/docs/default-source/gho-documents/global-health-estimates/ghe2019_cod_wbincome_2000_201933383745-a750-4d94-8491-fb209dcece6f.xlsx?sfvrsn=e7bafa8_5. Accessed 09 September 2023.

Ohishi M. Hypertension with diabetes mellitus: physiology and pathology. Hypertens Res. 2018;41(6):389–93.PubMedCrossRef

Bathgate RA, Halls ML, van der Westhuizen ET, et al. Relaxin family peptides and their receptors. Physiol Rev. 2013;93(1):405–80.PubMedCrossRef

Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. Faseb J. 2001;15(12):2187–95.PubMedCrossRef

Aragón-Herrera A, Feijóo-Bandín S, Anido-Varela L, et al. Relaxin‑2 as a Potential Biomarker in Cardiovascular Diseases. J Pers Med. 2022;12(7):1021.PubMedPubMedCentralCrossRef

Feijóo-Bandín S, Aragón-Herrera A, Rodríguez-Penas D, et al. Relaxin‑2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives. Front Physiol. 2017;8:599.PubMedPubMedCentralCrossRef

Hossain MA, Praveen P, Noorzi NA, et al. Development of Novel High-Affinity Antagonists for the Relaxin Family Peptide Receptor 1. Acs Pharmacol Transl Sci. 2023;6(5):842–53.PubMedCrossRef

Lian X, Beer-Hammer S, König GM, et al. RXFP1 Receptor Activation by Relaxin‑2 Induces Vascular Relaxation in Mice via a Gαi2-Protein/PI3Kß/γ/Nitric Oxide-Coupled Pathway. Front Physiol. 2018;9:1234.PubMedPubMedCentralCrossRef

Sasser JM, Cunningham MW Jr, Baylis C. Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Renal Physiol. 2014;307(12):F1355–F62.PubMedPubMedCentralCrossRef

10.

Snowdon VK, Lachlan NJ, Hoy AM, et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Med. 2017;14(2):e1002248.PubMedPubMedCentralCrossRef

11.

Xu Q, Chakravorty A, Bathgate RA, Dart AM, Du XJ. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension. 2010;55(5):1260–6.PubMedCrossRef

12.

Ponikowski P, Mitrovic V, Ruda M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J. 2014;35(7):431–41.PubMedCrossRef

13.

Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin‑2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39.PubMedCrossRef

14.

Metra M, Teerlink JR, Cotter G, et al. Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med. 2019;381(8):716–26.PubMedCrossRef

15.

Corcoran D, Radjenovic A, Mordi IR, et al. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Cardiovasc Res. 2021;117(1):320–9.PubMedCrossRef

16.

Kobalava Z, Villevalde S, Kotovskaya Y, et al. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. Br J Clin Pharmacol. 2015;79(6):937–45.PubMedPubMedCentralCrossRef

17.

Gifford FJ, Dunne PDJ, Weir G, et al. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Trials. 2020;21(1):260.PubMedPubMedCentralCrossRef

18.

Dahlke M, Halabi A, Canadi J, Tsubouchi C, Machineni S, Pang Y. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study. J Clin Pharmacol. 2016;56(4):474–83.PubMedCrossRef

19.

Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(4):1102–11.PubMedPubMedCentralCrossRef

20.

Sonaglia F, Milia P, Caserio M, et al. Efficacy and safety of oral porcine relaxin (pRLX) in adjunct to physical exercise in the treatment of peripheral arterial disease (PAD). Ital J Anat Embryol. 2013;118(1 Suppl):84–91.

21.

Gedikli O, Yilmaz H, Kiris A, et al. Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension. Blood Press. 2009;18(1–2:68–73.CrossRef

22.

Zhang X, Zhu M, Zhao M, et al. The plasma levels of relaxin‑2 and relaxin‑3 in patients with diabetes. Clin Biochem. 2013;46(16–17:1713–6.CrossRef

23.

Szepietowska B, Gorska M, Szelachowska M. Plasma relaxin concentration is related to beta-cell function and insulin sensitivity in women with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;79(3):e1–e3.PubMedCrossRef

24.

Gao X, Li H, Wang P, Chen H. Decreased Serum Relaxin‑2 Is Correlated with Impaired Islet β‑Cell Function in Patients with Unstable Angina and Abnormal Glucose Metabolism. Int Heart J. 2018;59(2):272–8.PubMedCrossRef

25.

Bryant GD, Panter ME, Stelmasiak T. Immunoreactive relaxin in human serum during the menstrual cycle. J Clin Endocrinol Metab. 1975;41(06):1065–9.PubMedCrossRef

26.

Nose-Ogura S, Yoshino O, Yamada-Nomoto K, et al. Oral contraceptive therapy reduces serum relaxin‑2 in elite female athletes. J Obstet Gynaecol Res. 2017;43(3):530–5.PubMedCrossRef

27.

Casey E, Anderson T, Wideman L, et al. Optimal Paradigms for Measuring Peak Serum Relaxin in Eumenorrheic, Active Females. Reprod Med Int. 2018;1:6.

28.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475]. Eur Heart J. 2018;39(33):3021–104.

29.

American Diabetes Association Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clin. Diabetes. 2022;40(1):10–38.

30.

Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney. Dis Kidney Inter Suppl. 2013;3(1):1–150.

31.

World Health Organization Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.

32.

World Health Organization Physical status: the use and interpretation of anthropometry. Report of a WHO. Ser, Vol. 854. Committee. World Health Organ Tech Rep: Expert; 1995. pp. 1–452.

33.

World Health Organization. Noncommunicable Diseases and Mental Health Cluster (2020) WHO STEPS Surveillance Manual: the WHO STEPwise approach to noncommunicable disease risk factor surveillance. https://www.who.int/docs/default-source/ncds/ncd-surveillance/steps/steps-manual.pdf?sfvrsn=c281673d_5. Accessed 09 September 2023.

34.

Bryant GD, Sassin JF, Weitzman ED, et al. Relaxin immunoactivity in human plasma during a 24-hr period. J Reprod Fertil. 1976;48(2):389–92.PubMedCrossRef

35.

Pintalhao M, Castro-Chaves P, Vasques-Novoa F, et al. Relaxin serum levels in acute heart failure are associated with pulmonary hypertension and right heart overload. Eur J Heart Fail. 2017;19(2):218–25.PubMedCrossRef

36.

Kupari M, Mikkola TS, Turto H, et al. Is the pregnancy hormone relaxin an important player in human heart failure? Eur J Heart Fail. 2005;7(2):195–8.PubMedCrossRef

37.

Aragón-Herrera A, Couselo-Seijas M, Feijóo-Bandín S, et al. Relaxin‑2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers. Sci Rep. 2022;12(1:22287.ADSCrossRef

38.

Wolf JM, Cameron KL, Clifton KB, et al. Serum relaxin levels in young athletic men are comparable with those in women. Orthopedics. 2013;36(2):128–31.PubMedCrossRef

39.

Dragoo JL, Castillo TN, Braun HJ, et al. Prospective correlation between serum relaxin concentration and anterior cruciate ligament tears among elite collegiate female athletes. Am J Sports Med. 2011;39(10):2175–80.PubMedCrossRef

40.

Owens BD, Cameron KL, Clifton KB, et al. Association Between Serum Relaxin and Subsequent Shoulder Instability. Orthopedics. 2016;39(4):e724–e8.PubMedCrossRef

41.

Nonhoff J, Ricke-Hoch M, Mueller M, et al. Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovasc Res. 2017;113(6):598–608.PubMedPubMedCentral

42.

Dragoo JL, Castillo TN, Korotkova TA, et al. Trends in serum relaxin concentration among elite collegiate female athletes. Int J Womens Health. 2011;3:19–24.PubMedPubMedCentral

43.

Giordano N, Papakostas P, Lucani B, et al. Serum relaxin in systemic sclerosis. J Rheumatol. 2005;32(11):2164–6.PubMed

44.

Binder C, Simon A, Binder L, et al. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat. 2004;87(2):157–66.PubMedCrossRef

45.

Krüger S, Graf J, Merx MW, et al. Relaxin kinetics during dynamic exercise in patients with chronic heart failure. Eur J Intern Med. 2004;15(1):54–6.PubMedCrossRef

46.

Wolf JM, Scher DL, Etchill EW, et al. Relationship of relaxin hormone and thumb carpometacarpal joint arthritis. Clin Orthop Relat Res. 2014;472(4):1130–7.PubMedCrossRef

47.

Schöndorf T, Lübben G, Hoopmann M, et al. Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. Gynecol Endocrinol. 2007;23(6):356–60.PubMedCrossRef

48.

Samuel CS, Royce SG, Hewitson TD, Denton KM, Cooney TE, Bennett RG. Anti-fibrotic actions of relaxin [published correction appears in Br J Pharmacol. 2017;174(24):4836]. Br J Pharmacol. 2017;174(10):962–976.

49.

Wolf JM, Williams AE, Delaronde S, et al. Relationship of serum relaxin to generalized and trapezial-metacarpal joint laxity. J Hand Surg Am. 2013;38(4):721–8.PubMedCrossRef

50.

Papadopoulos DP, Makris T, Perrea D, et al. Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension. J Clin Hypertens (greenwich). 2014;16(3):198–201.PubMedCrossRef

51.

Papadopoulos DP, Mourouzis I, Faselis C, et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (greenwich). 2013;15(5):333–6.PubMedCrossRef

52.

Sanidas E, Tsakalis K, Papadopoulos DP, et al. The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension. J Clin Hypertens (greenwich). 2019;21(1):48–52.PubMedCrossRef

53.

Bonanno A, Riccobono L, Bonsignore MR, et al. Relaxin in Obstructive Sleep Apnea: Relationship with Blood Pressure and Inflammatory Mediators. Respiration. 2016;91(1):56–62.PubMedCrossRef

54.

Lopez AY, Dereke J, Landin-Olsson M, et al. Plasma levels of relaxin‑2 are higher and correlated to C‑peptide levels in early gestational diabetes mellitus. Endocrine. 2017;57(3):545–7.CrossRef

55.

Wang P, Li HW, Wang YP, Chen H, Zhang P. Effects of recombinant human relaxin upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition. J Endocrinol Invest. 2009;32(3):242–7.PubMedCrossRef

56.

Bonner JS, Lantier L, Hocking KM, et al. Relaxin treatment reverses insulin resistance in mice fed a high-fat diet. Diabetes. 2013;62(9):3251–60.PubMedPubMedCentralCrossRef

57.

Bitto A, Irrera N, Minutoli L, et al. Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice. Clin Sci (lond). 2013;125(12):575–85.PubMedCrossRef

58.

Singh S, Simpson RL, Bennett RG. Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α). J Biol Chem. 2015;290(2):950–9.PubMedCrossRef

59.

Ng HH, Leo CH, Parry LJ, Ritchie RH. Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes. Front Pharmacol. 2018;9:501.PubMedPubMedCentralCrossRef

60.

Ng HH, Leo CH, Prakoso D, Qin C, Ritchie RH, Parry LJ. Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes. Sci Rep. 2017;7:39604.ADSPubMedPubMedCentralCrossRef

61.

Dschietzig TB, Krause-Relle K, Hennequin M, et al. Relaxin‑2 does not ameliorate nephropathy in an experimental model of type‑1 diabetes. Kidney Blood Press Res. 2015;40(1):77–88.PubMedCrossRef

62.

Wong SE, Samuel CS, Kelly DJ, et al. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes. Protein Pept Lett. 2013;20(9):1029–38.PubMedCrossRef

63.

Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786.PubMedPubMedCentralCrossRef

64.

Aragón-Herrera A, Feijóo-Bandín S, Abella V, et al. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue. Pharmacol Res. 2019;144:51–65.PubMedCrossRef

65.

Aragón-Herrera A, Feijóo-Bandín S, Moraña-Fernández S, et al. Relaxin has beneficial effects on liver lipidome and metabolic enzymes. Faseb J. 2021;35(7):e21737.PubMedCrossRef

66.

McGowan BM, Minnion JS, Murphy KG, et al. Central and peripheral administration of human relaxin‑2 to adult male rats inhibits food intake. Diabetes Obes Metab. 2010;12(12):1090–6.PubMedCrossRef

67.

Borghi C, Cicero AFG. Serum Uric Acid and Cardiometabolic Disease: Another Brick in the Wall? Hypertension. 2017;69(6:1011–3.CrossRef

Titel: Significance of plasma relaxin-2 levels in patients with primary hypertension and type 2 diabetes mellitus
verfasst von: Olena Pankova
Oleksii Korzh
Publikationsdatum: 07.03.2024
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-024-01035-x